Ocular Oncology News

NEW ORLEANS — Older age at presentation may be associated with a significantly decreased risk for germline mutation in children with solitary unilateral retinoblastoma, according to a presenter here.

Reduction in circulating tumor DNA appeared correlated with longer OS among patients with previously treated metastatic uveal melanoma who received tebentafusp, according to study results presented at the virtual ESMO Congress.

Cristina Puig-Saus, PhD, and Daniel S. Shin, MD, PhD, of UCLA Jonsson Comprehensive Cancer Center received a $1 million award from the U.S. Department of Defense for research into novel cell therapies for rare melanomas.

The FDA granted priority review to tebentafusp for treatment of adults with HLA-A*02:01-positive metastatic uveal melanoma.

A 68-year-old man was referred to the New England Eye Center neuro-ophthalmology clinic for evaluation of acute loss of vision in the left eye.

A 39-year-old man presented to the comprehensive ophthalmology service at the New England Eye Center with 6 weeks of daily headaches and blurry vision.

There was no significant difference in survival in eyes that underwent enucleation for uveal melanoma with extraocular extension between postoperative orbital external beam radiotherapy vs. observation, according to a poster presentation.

A 43-year-old stay-at-home mom was referred to the Tufts New England Eye Center for a newly identified orbital mass and vision changes in her right eye.

A conservative approach can be considered as a safe alternative to primary enucleation in children with advanced retinoblastoma in some cases, according to a presenter.

A 26-year-old woman was referred to the Lahey Clinic for evaluation of a recurrent conjunctival lesion of the right eye.